Search - Université Clermont Auvergne Access content directly

Filter your results

9 Results
authFullName_s : Arnaud Pigneux

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial

Arnaud Pigneux , Marie Béné , Louis-Rachid Salmi , Pierre-Yves Dumas , Jacques Delaunay et al.
Journal of Clinical Oncology, 2018, 36 (32), pp.3203-3210. ⟨10.1200/JCO.2018.78.7366⟩
Journal articles hal-02874606v1

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group

Thorsten Braun , Sophie Cereja , Sylvie Chevret , Emmanuel Raffoux , Marie Beaumont et al.
Cancer, 2015, 121 (14), pp.2393-2399. ⟨10.1002/cncr.29389⟩
Journal articles hal-01237097v1

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03441014v1

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

Lionel Adès , Xavier Thomas , Agnes Guerci Bresler , Emmanuel Raffoux , Olivier Spertini et al.
Haematologica, 2018, 103 (12), pp.2033-2039. ⟨10.3324/haematol.2018.198614⟩
Journal articles hal-02123075v1
Image document

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study

Arnaud Pigneux , Marie C Béné , Philippe Guardiola , Christian C Recher , Jean-Francois Hamel et al.
Journal of Clinical Oncology, 2017, 35 (4), pp.387-393. ⟨10.1200/JCO.2016.67.6213⟩
Journal articles inserm-01480651v1

Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Lionel Adès , Xavier Thomas , Agnes Cuerci-Bres , Raffoux Emmanuel , Olivier Spertini et al.
Blood, 2015, 126 (23), pp.451
Journal articles hal-01300812v1

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial

Anne Bouvier , Jean-Francois Hamel , Jacques Delaunay , Eric Delabesse , Pierre-Yves Dumas et al.
European Journal of Haematology, 2021, 107 (1), pp.111-121. ⟨10.1111/ejh.13626⟩
Journal articles hal-03604930v1

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Arnaud Pigneux , Christian Récher , Marie C. Bene , Julien Asselineau , Ariane C. Mineur et al.
Blood, 2015, 126 (23)
Journal articles hal-01295674v1
Image document

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Laetitia Largeaud , Pascale Cornillet-Lefebvre , Jean-François Hamel , Pierre-Yves Dumas , Naïs Prade et al.
Leukemia, 2021, 35 (5), pp.1291-1300. ⟨10.1038/s41375-020-01031-1⟩
Journal articles hal-03623649v1